{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:53:21Z","timestamp":1791942801578,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014907","name":"Gastric Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014907","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2P50CA127003"],"award-info":[{"award-number":["2P50CA127003"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmogo.2025.100278","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:28:25Z","timestamp":1767716905000},"page":"100278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinicopathologic correlates of claudin 18.2 expression in esophagogastric cancer at multiple expression levels"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4450-3350","authenticated-orcid":false,"given":"C.H.","family":"Maeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alkashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2653-4406","authenticated-orcid":false,"given":"A.","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2190-8969","authenticated-orcid":false,"given":"H.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7251-9635","authenticated-orcid":false,"given":"S.","family":"Bannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Simms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.N.","family":"Glickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0808","authenticated-orcid":false,"given":"S.J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmogo.2025.100278_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100278_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.36","article-title":"Gastric adenocarcinoma","volume":"3","author":"Ajani","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"23","key":"10.1016\/j.esmogo.2025.100278_bib3","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.3748\/wjg.14.3725","article-title":"Inoperable esophageal cancer and outcome of palliative care","volume":"14","author":"Besharat","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.esmogo.2025.100278_bib4","article-title":"Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial","volume":"9","author":"Rha","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"suppl 36","key":"10.1016\/j.esmogo.2025.100278_bib5","article-title":"EDGE-gastric arm A1: phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer","volume":"41","author":"Janjigian","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100278_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100278_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","article-title":"Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases","volume":"121","author":"Coati","year":"2019","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100278_bib8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmogo.2025.100278_bib9","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1038\/s41591-025-03898-y","article-title":"Evolution of claudin18.2 therapies in gastroesophageal cancers","volume":"31","author":"Klempner","year":"2025","journal-title":"Nat Mede"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100278_bib10","first-page":"3665","article-title":"Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies","volume":"19","author":"Moentenich","year":"2020","journal-title":"Oncol Lett"},{"issue":"10389","key":"10.1016\/j.esmogo.2025.100278_bib11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmogo.2025.100278_bib12","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.esmogo.2025.100278_bib13","doi-asserted-by":"crossref","first-page":"S858","DOI":"10.1016\/j.annonc.2023.09.1437","article-title":"1524P First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G\/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-cohort C","volume":"34","author":"Shen","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmogo.2025.100278_bib14","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.2024.42.16_suppl.4049","article-title":"Safety and efficacy results from the phase I\/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+\/HER2- locally advanced unresectable or metastatic gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma","volume":"42","author":"Liu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmogo.2025.100278_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.1499","article-title":"1433P A phase I\/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18.2+\/HER2- advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma","volume":"35","author":"Gong","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmogo.2025.100278_bib16","article-title":"CLARITY-PanTumor01: a phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors","volume":"42","author":"Raufi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmogo.2025.100278_bib17","article-title":"CLARITY-gastric 01: a randomized phase 3 study of AZD0901, a claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC\/GEJC)","volume":"43","author":"Janjigian","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmogo.2025.100278_bib18","article-title":"388MO Preliminary safety and efficacy of givastomig, a novel claudin 18.2\/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC)","volume":"36","author":"Klempner","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100278_bib19","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"issue":"11","key":"10.1016\/j.esmogo.2025.100278_bib20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/jpm11111095","article-title":"Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas","volume":"11","author":"Pellino","year":"2021","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100278_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"issue":"23","key":"10.1016\/j.esmogo.2025.100278_bib22","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1158\/1078-0432.CCR-24-4280","article-title":"A first-in-human study of givastomig, a CLDN18.2 and 4-1BB bispecific antibody, as monotherapy in patients with CLDN18.2-positive advanced or metastatic solid tumors","volume":"31","author":"Ku","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100278_bib23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/modpathol.2016.176","article-title":"A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2","volume":"30","author":"Jensen","year":"2017","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.esmogo.2025.100278_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100278_bib25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100278_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2023.100284","article-title":"Global ring study to investigate the comparability of total assay performance of commercial claudin 18 antibodies for evaluation in gastric cancer","volume":"104","author":"Jasani","year":"2024","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100278_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100778","article-title":"Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas","volume":"8","author":"Klempner","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100278_bib28","article-title":"Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100278_bib29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10120-024-01573-8","article-title":"Expression of therapy target molecules in esophagogastric junction and Barrett\u2019s adenocarcinoma","volume":"28","author":"Abe","year":"2025","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100278_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-12337-4","article-title":"The expression of the tight junction protein and therapeutical target claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma","volume":"15","author":"Pak","year":"2025","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100278_bib31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1440-1827.2007.02204.x","article-title":"Cdx2 transcription factor regulates claudin-3 and claudin-4 expression during intestinal differentiation of gastric carcinoma","volume":"58","author":"Satake","year":"2008","journal-title":"Pathol Int"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100278_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127300","article-title":"Intestinal stem cell markers in the intestinal metaplasia of stomach and Barrett\u2019s esophagus","volume":"10","author":"Jang","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100278_bib33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/path.1922","article-title":"Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype","volume":"208","author":"Sanada","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.esmogo.2025.100278_bib34","article-title":"Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.esmogo.2025.100278_bib35","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.21873\/anticanres.13919","article-title":"Clinical implications of claudin18.2 expression in patients with gastric cancer","volume":"39","author":"Baek","year":"2019","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100278_bib36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/cancers16030679","article-title":"Claudin 18.2 as a new biomarker in gastric cancer\u2014what should we know?","volume":"16","author":"Mathias-Machado","year":"2024","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100278_bib37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10120-023-01390-5","article-title":"Molecular profile of poorly cohesive gastric carcinoma with special reference to survival","volume":"26","author":"Koseki","year":"2023","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100278_bib38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100278_bib39","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2025.100278_bib40","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.esmogo.2025.100278_bib41","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","article-title":"The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial","volume":"31","author":"Ruan","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100278_bib42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","volume":"26","author":"Ruan","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10494","key":"10.1016\/j.esmogo.2025.100278_bib43","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825001475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825001475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:06:30Z","timestamp":1775315190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819825001475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"alternative-id":["S2949819825001475"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100278","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic correlates of claudin 18.2 expression in esophagogastric cancer at multiple expression levels","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100278"}}